NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026

Core Viewpoint - VIS-101 is a dual VEGF-A/ANG-2 inhibitor designed to offer more effective and durable treatment for patients with wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) [1][2][11] Company Overview - NovaBridge Biosciences is a global biotechnology platform company focused on accelerating access to innovative medicines [7] - The company combines business development expertise with clinical development to advance breakthrough assets [7] - NovaBridge is the majority shareholder of Visara, which holds global rights to VIS-101 outside of Greater China and certain Asian territories [3][6] Product Development - VIS-101 is currently undergoing a randomized, dose-ranging Phase 2a study for wet AMD [2][11] - The product is designed to provide potent and durable treatment benefits for wet AMD, DME, and RVO [2][11] - The company will host a virtual business update call to review Phase 2a clinical data for VIS-101 on March 9, 2026 [1] Pipeline and Collaborations - NovaBridge's pipeline includes givastomig, a bispecific antibody targeting Claudin 18.2 for gastric cancer, and ragistomig, a bispecific antibody for solid tumors [8][10] - The company also owns worldwide rights to uliledlimab, an anti-CD73 antibody targeting immunosuppression in cancer [10]